ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly

Summary

The primary objective of this study is to evaluate the efficacy of 15-week treatment with ALXN2420 versus placebo for decreasing insulin-like growth factor IGF-1 levels, when administered in combination with somatostatin analog (SSA) therapy to adult participants with acromegaly.

Timeline

Start

2025-10-28

Primary completion

2027-01-08

Completion

2027-11-11

Drugs

Indications